Compare TER & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TER | SNN |
|---|---|---|
| Founded | 1960 | 1856 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Electrical Products | Industrial Specialties |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7B | 14.0B |
| IPO Year | N/A | 1999 |
| Metric | TER | SNN |
|---|---|---|
| Price | $201.00 | $33.43 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 14 | 4 |
| Target Price | ★ $161.85 | $32.83 |
| AVG Volume (30 Days) | ★ 3.4M | 476.9K |
| Earning Date | 10-28-2025 | 03-02-2026 |
| Dividend Yield | 0.24% | ★ 2.19% |
| EPS Growth | N/A | ★ 59.91 |
| EPS | ★ 2.75 | 0.56 |
| Revenue | $2,859,571,000.00 | ★ $5,944,000,000.00 |
| Revenue This Year | $9.79 | $7.78 |
| Revenue Next Year | $22.74 | $5.13 |
| P/E Ratio | $72.91 | ★ $29.10 |
| Revenue Growth | 4.46 | ★ 5.35 |
| 52 Week Low | $65.77 | $23.69 |
| 52 Week High | $203.12 | $38.79 |
| Indicator | TER | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 71.05 | 48.01 |
| Support Level | $178.04 | $32.68 |
| Resistance Level | $173.83 | $33.56 |
| Average True Range (ATR) | 7.80 | 0.41 |
| MACD | 2.38 | 0.14 |
| Stochastic Oscillator | 95.88 | 78.51 |
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.